|
2026
|
G/S
|
Education and training services, namely, seminars, providing non-downloadable webinars, and works... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of neurodevelopmental and neurodegen... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment
of neurodevelopmental and neurodege... |
|
|
G/S
|
Financial and insurance consultation services, namely, patient advisory, support and consultancy ... |
|
|
G/S
|
Patient advisory and consultancy services regarding access to medical treatment, namely, providin... |
|
|
G/S
|
Education and training services, namely, providing seminars, non-downloadable webinars, and works... |
|
|
G/S
|
Healthcare services, namely, patient advisory, medical support and consultancy services regarding... |
|
|
Invention
|
Methods for reducing htt expression.
Provided herein are methods of administering ISIS 443139 fo... |
|
|
Invention
|
Compounds and methods for reducing kcnt1 expression.
Provided are compounds, methods, and pharma... |
|
|
G/S
|
Medical services; medical information services; providing medical and healthcare information for ... |
|
|
Invention
|
Compounds and methods for reducing atxn3 expression.
Provided are compounds, methods, and pharma... |
|
|
G/S
|
Pharmaceutical preparations and substances, biological
preparations and substances, therapeutic ... |
|
|
G/S
|
Education and training services in the field of healthcare; education and training services in th... |
|
|
G/S
|
Pharmaceutical preparations and substances; biological preparations and substances for medical pu... |
|
|
G/S
|
Providing financial information regarding patient reimbursement for pharmaceutical preparations a... |
|
|
G/S
|
Pharmaceutical preparations and substances, biological preparations and substances, therapeutic p... |
|
|
G/S
|
Training services in the field of healthcare; Training services in the field of pharmaceuticals; ... |
|
|
G/S
|
Medical and healthcare services; Providing medical information, healthcare information and medica... |
|
|
Invention
|
Compositions for modulating ataxin 2 expression.
Disclosed herein are antisense compounds and me... |
|
|
G/S
|
Financial and insurance consultation services, namely,
patient advisory, support and consultancy... |
|
|
Invention
|
Compositions for modulating c9orf72 expression.
Disclosed herein are compositions and methods fo... |
|
|
Invention
|
Conjugated antisense compounds and their use.
Provided herein are oligomeric compounds with conj... |
|
|
Invention
|
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds.
... |
|
|
Invention
|
Compounds and methods for modulating angiotensinogen expression.
Disclosed herein are compositio... |
|
|
Invention
|
Compounds and methods for modulating hnrnph2 expression. Provided are oligomeric agents, modified... |
|
2025
|
Invention
|
Lipid encapsulated nanoparticles. The present disclosure provides an ionizable lipid of Formula (... |
|
|
Invention
|
Compositions and methods for modulating ttr expression.
Provided herein are oligomeric compounds... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of edema, namely, hereditary angioed... |
|
|
G/S
|
Pharmaceutical preparations and substances in the field of neurodevelopmental and neurodegenerati... |
|
|
Invention
|
Methods for safely reducing thrombopoietin.
Provided herein are methods, compounds, and composit... |
|
|
Invention
|
Compounds and methods for reducing pacs1 expression. Provided are oligomeric agents, methods, and... |
|
|
G/S
|
Pharmaceutical preparations and substances in the field of
neurodevelopmental and neurodegenerat... |
|
|
Invention
|
Compounds and methods for modulating alpha-synuclein expression. Provided are oligomeric agents, ... |
|
|
Invention
|
Patterned modified oligonucleotides for extended duration of action. Provided are oligomeric agen... |
|
|
G/S
|
Patient advisory, support and consultancy services regarding access to medical treatment of hered... |
|
|
Invention
|
Linkage modified oligomeric compounds and uses thereof.
The present disclosure provides oligomer... |
|
|
Invention
|
Cell-targeting complexes and uses thereof. Provided are transferrin receptor binding VHH domains ... |
|
|
Invention
|
Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) po... |
|
|
Invention
|
Compositions and methods for treating and preventing prekallikrein-associated conditions.
Provid... |
|
|
Invention
|
Compositions and methods for modulating complement factor b expression.
The present embodiments ... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioede... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment
of edema, namely hereditary angioed... |
|
|
Invention
|
Methods and compositions for reducing diacyglycerol acyltransferase 2 (dgat2). Provided herein ar... |
|
|
Invention
|
Compositions and methods for modulating mecp2 expression.
Disclosed herein are compounds and met... |
|
|
Invention
|
Linkage modified oligomeric agents and uses thereof. The present disclosure provides oligomeric c... |
|
|
Invention
|
Compounds and methods for modulating apoe expression. Provided are oligomeric agents, pharmaceuti... |
|
|
Invention
|
Patterned modified oligonucleotides. Provided are oligomeric agents, methods, and pharmaceutical ... |
|
|
Invention
|
Compounds and methods for modulating apoe expression.
Provided are oligomeric agents, pharmaceut... |
|
|
Invention
|
Patterned double stranded oligonucleotides. Provided are oligomeric agents, methods, and pharmace... |
|
|
Invention
|
Compounds and methods for modulating smn2.
Provided are compounds, methods, and pharmaceutical c... |
|
|
G/S
|
Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of... |
|
|
G/S
|
Pharmaceuticals for treatment of genetic diseases and
disorders; pharmaceuticals for treatment o... |
|
|
G/S
|
Medical services; medical information services; providing a website featuring medical and healthc... |
|
|
Invention
|
Methods and compositions for modulating apolipoprotein (a) expression.
Disclosed herein are anti... |
|
|
Invention
|
Compositions and methods for modulating apolipoprotein c-iii expression.
Provided herein are oli... |
|
|
Invention
|
Compounds and methods for reducing prion expression.
Provided are compounds, methods, and pharma... |
|
|
Invention
|
Selective antisense compounds and uses thereof.
The present invention provides oligomeric compou... |
|
|
Invention
|
Oligomeric compounds comprising bicyclic nucleotides and uses thereof.
The present invention pro... |
|
2024
|
Invention
|
Modified compounds and uses thereof.
The present disclosure provides oligomeric compound compris... |
|
|
Invention
|
Antisense compounds targeted to cln3 and uses thereof.
The present invention provides compounds ... |
|
|
Invention
|
Compounds and methods for modulating ube3a-ats.
Provided are compounds, methods, and pharmaceuti... |
|
2023
|
Invention
|
Methods for deprotecting and purifying oligonucleotide compounds.
The present disclosure provide... |
|
|
Invention
|
Methods for modulating complement factor b expression.
Provided herein are methods of ameliorati... |
|
|
Invention
|
Rnai agents for modulating snca.
Provided are antisense agents, pharmaceutical compositions, and... |
|
|
Invention
|
Rnai agents of prion expression.
Provided are RNAi agents, pharmaceutical compositions, and meth... |
|
2022
|
Invention
|
Compounds and methods for reducing glycogen synthase 1.
Provided are compounds, methods, and pha... |
|
|
Invention
|
Compounds and methods for reducing tau expression.
Provided are RNAi agents, methods, and pharma... |
|
2015
|
Invention
|
Compositions and methods for modulating complement factor b expression. The present embodiments p... |
|
2014
|
Invention
|
Compositions and methods for modulating apolipoprotein (a) expression. Provided herein are oligom... |
|
|
Invention
|
Compositions and methods for modulating hbv and ttr expression. Provided herein are oligomeric co... |
